LONDON (Reuters) - Danish drugmaker Lundbeck won a European green light on Friday for its new alcohol dependency drug Selincro, boosting its product portfolio at a time when its biggest product faces a big drop in sales. Lundbeck needs new drugs to replace lost sales from antidepressant Cipralex, sold as Lexapro in the United States and Japan, which is now coming off patent. The European Medicines Agency (EMA) said on Friday it recommended approval of Selincro in conjunction with psychosocial support for the reduction of alcohol consumption in adults with alcohol dependence. ... Original Source
No comments:
Post a Comment